Search the website

Fulltext search

Search results

Categories

Human Remove Human filter Veterinary (33) Apply Veterinary filter

Medicine name

Active substance / international non-proprietary name (INN) / common name

Medicine

European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter Referrals Remove Referrals filter Summaries of opinion (10) Apply Summaries of opinion filter Withdrawn applications (30) Apply Withdrawn applications filter Orphan designations (21) Apply Orphan designations filter Direct healthcare professional communication (4) Apply Direct healthcare professional communication filter

Product number

Patient safety

Yes (1) Apply Yes filter

Authorisation status

Authorised (343) Apply Authorised filter Refused (3) Apply Refused filter Withdrawn (76) Apply Withdrawn filter

ATC code

Marketing authorisation date

From:

To:

Marketing authorisation holder

Pharmacotherapeutic group

Date of opinion

From:

To:

PIP decision type

P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) (4) Apply P: decision agreeing on a investigation plan, with or without partial waiver(s) and or deferral(s) filter PM: decision on the application for modification of an agreed PIP (26) Apply PM: decision on the application for modification of an agreed PIP filter W: decision granting a waiver in all age groups for all conditions or indications (10) Apply W: decision granting a waiver in all age groups for all conditions or indications filter

PIP condition / indication

Pharmaceutical form(s)

Route(s) of administration

Decision date

From:

To:

PIP compliance check

Yes (10) Apply Yes filter

Compliance procedure number

Referral name

Referral status

European Commission final decision (6) Apply European Commission final decision filter

Referral safety status

Yes (3) Apply Yes filter

Referral type

Article 20 procedures (3) Apply Article 20 procedures filter Article 31 referrals (3) Apply Article 31 referrals filter

Referral reference number

Referral decision making model

PRAC-CAT-CHMP-EC (1) Apply PRAC-CAT-CHMP-EC filter PRAC-CHMP-EC (4) Apply PRAC-CHMP-EC filter

Referral authorisation model

Centrally and nationally authorised products (mixed) (3) Apply Centrally and nationally authorised products (mixed) filter Centrally authorised product(s) (3) Apply Centrally authorised product(s) filter

Referral PRAC recommendation

Risk minimisation measures (3) Apply Risk minimisation measures filter Variation (1) Apply Variation filter

Referral procedure start date

From:

To:

Referral PRAC recommendation date

From:

To:

Medicine type

Accelerated assessment Remove Accelerated assessment filter Biosimilar Remove Biosimilar filter Generic Remove Generic filter Additional monitoring (580) Apply Additional monitoring filter Conditional approval (81) Apply Conditional approval filter Exceptional circumstances (57) Apply Exceptional circumstances filter Orphan medicine (249) Apply Orphan medicine filter

Related medicine

Therapeutic area

Topic

Last updated

From:

To:

This week This month Last week Last month

First published

From:

To:

468 results

Remove all filtersRemove all filters

Medicine type Generic Remove Generic filter Biosimilar Remove Biosimilar filter Accelerated assessment Remove Accelerated assessment filter

Categories Human Remove Human filter

Medicine Referrals Remove Referrals filter European public assessment reports (EPAR) Remove European public assessment reports (EPAR) filter Paediatric investigation plans Remove Paediatric investigation plans filter

Sort by

List item

Human medicine European public assessment report (EPAR): Kisplyx (updated)

lenvatinib mesilate, Carcinoma, Renal Cell
Date of authorisation: 25/08/2016, , Revision: 18, Authorised, Last updated: 31/03/2023
List item

Human medicine European public assessment report (EPAR): Capecitabine Medac (updated)

capecitabine, Colorectal Neoplasms
Date of authorisation: 19/11/2012, , Revision: 13, Authorised, Last updated: 31/03/2023
List item

Human medicine European public assessment report (EPAR): Grasustek (updated)

pegfilgrastim, Neutropenia
Date of authorisation: 20/06/2019, , , Revision: 4, Authorised, Last updated: 31/03/2023
List item

Human medicine European public assessment report (EPAR): Tegsedi (updated)

inotersen sodium, Amyloidosis
Date of authorisation: 06/07/2018, , , Revision: 13, Authorised, Last updated: 31/03/2023
List item

Human medicine European public assessment report (EPAR): Dasatinib Accord (updated)

dasatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Date of authorisation: 24/03/2022, , Revision: 1, Withdrawn, Last updated: 30/03/2023
List item

Human medicine European public assessment report (EPAR): Dasatinib Accordpharma (updated)

dasatinib, Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myelogenous, Chronic, BCR-ABL Positive
Date of authorisation: 24/03/2022, , Revision: 1, Withdrawn, Last updated: 30/03/2023
List item

Human medicine European public assessment report (EPAR): Azacitidine Accord (updated)

azacitidine, Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Leukemia, Myeloid, Acute
Date of authorisation: 13/02/2020, , Revision: 6, Authorised, Last updated: 29/03/2023
List item

Human medicine European public assessment report (EPAR): Febuxostat Mylan (updated)

febuxostat, Hyperuricemia; Arthritis, Gouty; Gout
Date of authorisation: 15/06/2017, , Revision: 9, Authorised, Last updated: 29/03/2023
List item

Human medicine European public assessment report (EPAR): Nyvepria (updated)

pegfilgrastim, Neutropenia
Date of authorisation: 18/11/2020, , , Revision: 5, Authorised, Last updated: 29/03/2023
List item

Human medicine European public assessment report (EPAR): Memantine Mylan (updated)

memantine hydrochloride, Alzheimer Disease
Date of authorisation: 21/04/2013, , Revision: 10, Authorised, Last updated: 29/03/2023
List item

Human medicine European public assessment report (EPAR): Arsenic trioxide Mylan (updated)

Arsenic trioxide, Leukemia, Promyelocytic, Acute
Date of authorisation: 01/04/2020, , Revision: 4, Authorised, Last updated: 29/03/2023
List item

Human medicine European public assessment report (EPAR): Deferasirox Mylan (updated)

deferasirox, Iron Overload; beta-Thalassemia
Date of authorisation: 26/09/2019, , Revision: 9, Authorised, Last updated: 28/03/2023
List item

Human medicine European public assessment report (EPAR): Imraldi (updated)

adalimumab, Spondylitis, Ankylosing; Arthritis, Rheumatoid; Uveitis; Colitis, Ulcerative; Psoriasis; Arthritis, Psoriatic; Crohn Disease; Hidradenitis Suppurativa; Arthritis
Date of authorisation: 24/08/2017, , Revision: 20, Authorised, Last updated: 24/03/2023
List item

Human medicine European public assessment report (EPAR): Kanjinti (updated)

trastuzumab, Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 16/05/2018, , Revision: 10, Authorised, Last updated: 24/03/2023
List item

Human medicine European public assessment report (EPAR): Levetiracetam Accord (updated)

levetiracetam, Epilepsy
Date of authorisation: 03/10/2011, , Revision: 15, Authorised, Last updated: 24/03/2023
List item

Human medicine European public assessment report (EPAR): Miglustat Dipharma (updated)

miglustat, Gaucher Disease
Date of authorisation: 18/02/2019, , Revision: 5, Authorised, Last updated: 24/03/2023
List item

Human medicine European public assessment report (EPAR): Truvelog Mix 30 (updated)

insulin aspart, Diabetes Mellitus
Date of authorisation: 25/04/2022, , , Revision: 1, Authorised, Last updated: 23/03/2023
List item

Human medicine European public assessment report (EPAR): Terrosa (updated)

teriparatide, Osteoporosis
Date of authorisation: 04/01/2017, , , Revision: 6, Authorised, Last updated: 23/03/2023
List item

Human medicine European public assessment report (EPAR): Vegzelma (updated)

bevacizumab, Colorectal Neoplasms; Breast Neoplasms; Ovarian Neoplasms; Fallopian Tube Neoplasms; Peritoneal Neoplasms; Carcinoma, Non-Small-Cell Lung; Carcinoma, Renal Cell; Uterine Cervical Neoplasms
Date of authorisation: 17/08/2022, , , Revision: 2, Authorised, Last updated: 22/03/2023
List item

Human medicine European public assessment report (EPAR): Darzalex (updated)

Daratumumab, Multiple Myeloma
Date of authorisation: 20/05/2016, , , Revision: 20, Authorised, Last updated: 22/03/2023
List item

Human medicine European public assessment report (EPAR): Insulin lispro Sanofi (updated)

insulin lispro, Diabetes Mellitus
Date of authorisation: 19/07/2017, , Revision: 8, Authorised, Last updated: 22/03/2023
List item

Human medicine European public assessment report (EPAR): Herzuma (updated)

trastuzumab, Stomach Neoplasms; Breast Neoplasms
Date of authorisation: 09/02/2018, , Revision: 19, Authorised, Last updated: 22/03/2023
List item

Human medicine European public assessment report (EPAR): Lamivudine/Zidovudine Teva (updated)

lamivudine, zidovudine, HIV Infections
Date of authorisation: 28/02/2011, , Revision: 16, Withdrawn, Last updated: 21/03/2023
List item

Human medicine European public assessment report (EPAR): Nevirapine Teva (updated)

nevirapine, HIV Infections
Date of authorisation: 30/11/2009, , Revision: 11, Withdrawn, Last updated: 21/03/2023
List item

Human medicine European public assessment report (EPAR): Docetaxel Accord (updated)

docetaxel, Head and Neck Neoplasms; Carcinoma, Non-Small-Cell Lung; Adenocarcinoma; Prostatic Neoplasms; Breast Neoplasms
Date of authorisation: 22/05/2012, , Revision: 16, Authorised, Last updated: 20/03/2023

Load more

468 results

Human medicine European public assessment report (EPAR): Kisplyx (updated)

Human medicine European public assessment report (EPAR): Capecitabine Medac (updated)

Human medicine European public assessment report (EPAR): Grasustek (updated)

Human medicine European public assessment report (EPAR): Tegsedi (updated)

Human medicine European public assessment report (EPAR): Dasatinib Accord (updated)

Human medicine European public assessment report (EPAR): Dasatinib Accordpharma (updated)

Human medicine European public assessment report (EPAR): Azacitidine Accord (updated)

Human medicine European public assessment report (EPAR): Febuxostat Mylan (updated)

Human medicine European public assessment report (EPAR): Nyvepria (updated)

Human medicine European public assessment report (EPAR): Memantine Mylan (updated)

Human medicine European public assessment report (EPAR): Arsenic trioxide Mylan (updated)

Human medicine European public assessment report (EPAR): Deferasirox Mylan (updated)

Human medicine European public assessment report (EPAR): Imraldi (updated)

Human medicine European public assessment report (EPAR): Kanjinti (updated)

Human medicine European public assessment report (EPAR): Levetiracetam Accord (updated)

Human medicine European public assessment report (EPAR): Miglustat Dipharma (updated)

Human medicine European public assessment report (EPAR): Truvelog Mix 30 (updated)

Human medicine European public assessment report (EPAR): Terrosa (updated)

Human medicine European public assessment report (EPAR): Vegzelma (updated)

Human medicine European public assessment report (EPAR): Darzalex (updated)

Human medicine European public assessment report (EPAR): Insulin lispro Sanofi (updated)

Human medicine European public assessment report (EPAR): Herzuma (updated)

Human medicine European public assessment report (EPAR): Lamivudine/Zidovudine Teva (updated)

Human medicine European public assessment report (EPAR): Nevirapine Teva (updated)

Human medicine European public assessment report (EPAR): Docetaxel Accord (updated)